NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/10/2022
Voltar para busca
Dado oficial do USPTO
MACROFINDER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MACROFINDER
ST13
US500000079077372Classe
1, 5, 42
Pedido
79077372
Registro
3950034
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
52
Atualização mais recente
29/10/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
29/10/2009
Data de registro
26/04/2011
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/11/2021
Última transação
26/11/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Allschwil, CH
Examinador
KING, LINDA M
Unidade examinadora
M70
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
Polyphor AG
Representantes
Scott D. Woldow Smith, Gambrell, Russell, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry and science
Classe 5
Pharmaceutical anti-allergic preparations and substancesPharmaceutical for the treatment of erectile dysfunctionPharmaceutical preparationsanticoagulantsPharmaceutical preparationsantidepressantsPharmaceutical preparationsappetite suppressantsPharmaceutical preparations for use in chemotherapyPharmaceutical preparation for the treatment of goutPharmaceutical preparations for the treatment of heart rhythm disordersPharmaceutical preparations for the treatment of stem cell mobilizationPharmaceutical preparations for the treatment of infectious diseasesPharmaceutical preparations acting on the central nervous systemPharmaceutical preparations and substances for the treatment of gastro-intestinal diseasesPharmaceutical preparations for animal skincarePharmaceutical preparations for inhalation for the treatment of pulmonary hypertensionPharmaceutical preparations for ocular or intraocular surgeryPharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosisPharmaceutical preparations for treating allergic rhinitis and asthmaPharmaceutical preparations for treating diabetesPharmaceutical preparations for treating skin disordersPharmaceutical preparations for use in dermatologyPharmaceutical preparations for woundsPharmaceutical preparations for use in urologyPharmaceutical preparationsa blood clotting aid and delivery system for use in humansPharmaceutical products and preparations against dry skin caused by pregnancyPharmaceutical products and preparations for chloasmaPharmaceutical products and preparations for hydrating the skin during pregnancyPharmaceutical products and preparations for pregnancy blemishesPharmaceutical products and preparations for preventing skin blemishes during pregnancyPharmaceutical products and preparations to prevent stretch marksPharmaceutical products and preparations to prevent swelling in the legsPharmaceutical products for ophthalmological usePharmaceutical products for the treatment of bone diseasesPharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancerPharmaceutical products for treating respiratory diseases and asthmaPharmaceutical skin lotionsPharmaceutical solutions used in dialysisPharmaceuticals for the treatment of erectile dysfunctionPharmaceuticalsantihelminticsPharmaceuticalsinducers of erectionsPharmaceuticalslipid lowering agentsPharmaceuticalspsychotropicsPharmaceuticalsanti-infectives; and sanitary preparations for medical purposes; dietetic foods adapted for medical usemedical plastersdressings for woundsburnssurgery; dental impression materials; disinfectants for hygienic purposes
Classe 42
Scientific and technological services in the nature of scientific research in the fields of pharmaceuticals and bio-chemistry ; design for others in the fields of pharmaceuticals and bio-chemistry; industrial analysis and research services in the fields of pharmaceuticals and bio-chemistry
Publicações
Histórico de despachos e eventos da marca no USPTO.
52 publicações encontradas
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
19/09/2022
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
29/08/2022
INPC
INVALIDATION PROCESSED
29/08/2022
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
26/07/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2022
C71T
CANCELLED SECTION 71
26/11/2021
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
26/04/2020
RNWL
INTERNATIONAL REGISTRATION RENEWED
05/12/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/07/2018
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
06/04/2018
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
22/02/2018
INPC
INVALIDATION PROCESSED
22/02/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
21/02/2018
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
21/06/2017
71AG
REGISTERED-SEC.71 ACCEPTED
21/06/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/06/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/06/2017
ES71
TEAS SECTION 71 RECEIVED
18/04/2017
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/05/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/09/2011
FIMP
FINAL DISPOSITION PROCESSED
21/09/2011
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/07/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
26/04/2011
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/02/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/02/2011
PUBO
PUBLISHED FOR OPPOSITION
08/02/2011
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/02/2011
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/02/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/01/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/01/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2010
ALIE
ASSIGNED TO LIE
22/12/2010
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
19/11/2010
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
30/07/2010
GNFR
FINAL REFUSAL E-MAILED
30/07/2010
CNFR
FINAL REFUSAL WRITTEN
30/07/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/07/2010
ALIE
ASSIGNED TO LIE
15/07/2010
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/06/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/06/2010
RFNT
REFUSAL PROCESSED BY IB
05/03/2010
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2010
RFRR
REFUSAL PROCESSED BY MPU
08/02/2010
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/02/2010
CNRT
NON-FINAL ACTION WRITTEN
04/02/2010
DOCK
ASSIGNED TO EXAMINER
03/02/2010
MAFR
APPLICATION FILING RECEIPT MAILED
26/01/2010
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/01/2010
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/01/2010
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MACROFINDER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.